Sinotherapeutics Inc.

688247

CNE100005PL9

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
9.4 ^CNY	+0.11%		-3.59%	-14.39%

04-29	Sinotherapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-02	Tranche Update on Sinotherapeutics Inc.'s Equity Buyback Plan announced on February 21, 2024.	CI

Tranche Update on Sinotherapeutics Inc.'s Equity Buyback Plan announced on February 21, 2024.

April 01, 2024

From February 19, 2024 to March 31, 2024, the company has repurchased 3,860,109 shares, representing 0.85% for CNY 32.31 million. With this, the company has completed the repurchase of 3,860,109 shares, representing 0.85% for CNY 32.31 million under the buyback announced on February 21, 2024.

Latest news about Sinotherapeutics Inc.

Sinotherapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Tranche Update on Sinotherapeutics Inc.'s Equity Buyback Plan announced on February 21, 2024.	04-01	CI
Sinotherapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Sinotherapeutics Inc. announces an Equity Buyback for CNY 70 million worth of its shares.	02-20	CI
Sinotherapeutics Inc. authorizes a Buyback Plan.	02-18	CI
Sinotherapeutics Gets Nod for Mesalazine Tablets; Shares Drop 7%	02-05	MT
Sinotherapeutics Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23	CI
Sinotherapeutics' Unit Gets Registration Certificate for Sevelamer Carbonate Tablets	26/09/23	MT
Sinotherapeutics Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23	CI
Sinotherapeutics Inc.(SHSE:688247) added to Shanghai Stock Exchange A Share Index	25/08/23	CI
Sinotherapeutics Inc.(SHSE:688247) added to Shanghai Stock Exchange Composite Index	25/08/23	CI
Sinotherapeutics Gets US FDA Nod for Arthritis Drug	10/08/23	MT
Sinotherapeutics Signs Product Licensing Deal With US Drugmaker Lannett	07/08/23	MT
FDA Greenlights Sinotherapeutics' Mesalazine Enteric-Coated Tablets	17/05/23	MT
Sinotherapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Sinotherapeutics Drug Selected in China's Centralized Drug Procurement	13/04/23	MT
Sinotherapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23	CI
Sinotherapeutics’ Antifungal Drug Added to China’s Medical Insurance Catalog	19/01/23	MT
Sinotherapeutics Inc. has completed an IPO in the amount of CNY 424.8358 million.	22/08/22	CI

Chart Sinotherapeutics Inc.

Duration

Period

More charts

Company Profile

Sinotherapeutics Inc is China-based company mainly engaged in the research and development, commercial production and sales of pharmaceutical preparations. The Company's main businesses include research and development, production and sales of generic drugs, as well as contract research and development organization (CRO) services. The Company mainly operates in the domestic market and overseas markets.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SINOTHERAPEUTICS INC.	-14.39%	585M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.63%	44.12B
OTSUKA HOLDINGS CO., LTD.	+22.99%	22.71B
SANDOZ GROUP AG	+18.22%	15.15B
CIPLA LIMITED	+12.66%	13.61B
ZYDUS LIFESCIENCES LIMITED	+60.18%	13.34B
ONO PHARMACEUTICAL CO., LTD.	-8.35%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.92%	5.63B